Delisting risk
Aspire Biopharma
Developer of sublingual drug and supplement formulations, including aspirin candidates and Buzz Bomb.
$8.51
After-hours close−0.01 (−0.12%)
At close$8.52(+3.15%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 0.73%845 sharesInsiders 0.01%17 sharesOther 99.26%114.5K shares
Shares outstanding 115.4K · Float 77.7K · 67.4% free float
A split settled inside the quarter being compared, so quarter-on-quarter change is not shown.
Institutions13F, as of Mar 31, 2026
2 holders · 845 shares
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Crossingbridge Advisors, LLC | 812 | 0.70% | May 14, 2026 | |
| Hallmark Capital Management Inc | 33 | 0.03% | May 6, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Gary Shirinyan | 7.70% | 13G | Aug 10, 2026 ↗ | |
| Highbridge Capital Management, LLC | 5.20% | 13G | May 15, 2026 ↗ | |
| Rubenbauer Alois Ryan III | 5.00% | 13G | Jul 2, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Donald G. Fell | director | 17 | 0.01% | Jun 10, 2025 |
1 ten-percent owner holds 2.4K shares by Form 4, outside the officers-and-directors figure above · 1 person has not refiled in the last 18 months (3.6K shares), so they are not in the figure above
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.